The Effect of Staple Line Reinforcement Procedures on Postoperative Nausea and Vomiting in Sleeve Gastrectomy

November 29, 2023 updated by: Sakarya University

Obesity is a significant public health problem. The only long-term effective treatment method is surgery. The most common surgical procedure is laparoscopic sleeve gastrectomy (LSG). However, after LSG, complications such as gastroesophageal reflux disease (GERD), insufficient weight loss, stenosis in the remnant stomach, and bleeding or leakage in the staple line (SL) may be encountered. The most severe complications are leakage and bleeding in sleeve gastrectomy, which can lead to many morbidities and mortality. Strengthening the staple line is an important option to prevent these complications. Methods such as fibrin adhesives, bioabsorbable patches and stitching of the stapler line are used to strengthen the stapler line.

Nausea and vomiting, which occur in the postoperative period in 40% of patients who have undergone abdominal surgery and constitute a serious problem, are detected at an even higher rate in patients who have undergone bariatric surgery. Additionally, strengthening the staple line with various methods may increase the incidence of nausea and vomiting after LSG. Although there are studies in the literature investigating whether strengthening the staple line with buttress material or suture in laparoscopic sleeve gastrectomy affects the incidence of postoperative nausea and vomiting, there is no study investigating the effect of strengthening the staple line with fibrin glue on the incidence of postoperative nausea and vomiting.

This prospective study aims to reveal whether there is a difference between strengthening the staple line with fibrin glue or suture in LSG regarding the incidence of postoperative nausea and vomiting and its effects on quality of life.

Study Overview

Detailed Description

Bleeding and leaks may occur in the stapler line after sleeve gastrectomy. To prevent these complications, the staple line can be strengthened. More than 60% of bariatric surgeons perform interventions to strengthen the staple line in sleeve gastrectomy.

Two surgeons will perform the operations. One of the surgeons will suture the staple line. The other will apply fibrin glue to the stapler line.

Study: It will be held between June 2023 and June 2024. The same anaesthesia protocol will be applied to all patients during the surgery; All patients will be administered fentanyl 2 mg kg-1, propofol 2.5 mg kg-1 and rocuronium 0.6 mg kg-1 based on lean body weight (LBW) for anaesthesia induction after 3 minutes of preoxygenation. After orotracheal intubation is performed under the guidance of a video laryngoscope and endotracheal intubation is confirmed, 1.0 Minimum alveolar concentration (MAC) value sevoflurane and 1:1 oxygen-air will be used for anaesthesia maintenance. Additional doses of rocuronium were administered if surgically necessary. Ventilation will be applied with a tidal volume of 6-8 ml kg-1 according to the ideal body weight for lung protective ventilation, along with a respiratory frequency at a level to ensure normocapnia (EtCO2 35-45 mmHg). For intraoperative analgesia, remifentanil infusion will be administered at a 0.1-0.3 mcg kg-1 min-1 dose according to ideal body weight. All patients will be given 0.15 mg kg-1 (maximum 16 mg) of ondansetron as an antiemetic. In recovery, sugammadex will be used at a 4-8 mg kg-1 dose to reverse the neuromuscular blockade. For acute postoperative analgesia, 100 mg tramadol, 1000 mg paracetamol and 50 mg dexketoprofen will be administered. No routine postoperative antiemetic medication will be used.

Quality of life index and nausea and vomiting score survey forms will be filled out for patients in the preoperative period, at the 6th, 24th hour and 1st postoperative hour. According to these filled-out forms, the patient's nausea and vomiting scores and quality of life scores will be calculated. Patients included in both groups will be compared to these scores.

This study aims to determine whether there is a difference in strengthening the staple line with fibrin glue or sutures in sleeve gastrectomy regarding the incidence of postoperative nausea and vomiting and its effects on quality of life.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Adapazarı
      • Sakarya, Adapazarı, Turkey, 54100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with a body mass index of 40 kg/m2 and above

Exclusion Criteria:

  • Patients with hiatal hernia, gastritis or ulcer detected during endoscopy
  • Smoker
  • Patients who have previously had another bariatric procedure
  • Patients who have previously undergone gastrointestinal system surgery
  • Patients with any contraindications for bariatric surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fibrin Glue Group
Sleeve gastrectomy will be performed on morbidly obese patients, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. Then, Fibrin Glue (TisseelTM-Baxter, USA) will be applied to the staple line.
The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.
The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.
Active Comparator: Suture Group
Sleeve gastrectomy will be performed on morbidly obese patients, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. Then, the stapler line will be sutured with continuous sutures with 3/0 prolene suture, with the stapler line inverted.
The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.
The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative nausea and vomiting intensity scale (6. hours)
Time Frame: Postoperative 6 hours

Question 1. Have you vomited or had dry-retching?

  1. No 0 point
  2. Once or twice 2 point
  3. Three or more times 50 points

Question 2. Have you experienced a feeling of nausea? If yes, has your feeling interfered with being able to get out of bed, walking, eating or drinking?

  1. No 0 point
  2. Sometimes 1 point
  3. Often or most of the time 2 point
  4. All of the time 25 point

Question 3. Has your nausea been mostly:

  1. Varying ("comes and goes") 1point
  2. Constant 2 point

Question 4. What was the duration of your feeling of nausea (in hours)?

…, … (hours). If the answer to Q1=c), score=50 Otherwise, select the highest score of Q1 or Q2, the multiply x Q3 x Q4 Postoperative nausea and vomiting intensity score:

Postoperative 6 hours
Postoperative nausea and vomiting intensity scale (24. hours)
Time Frame: Postoperative 24 hours

Question 1. Have you vomited or had dry-retching?

  1. No 0 point
  2. Once or twice 2 point
  3. Three or more times 50 points

Question 2. Have you experienced a feeling of nausea? If yes, has your feeling interfered with being able to get out of bed, walking, eating or drinking?

  1. No 0 point
  2. Sometimes 1 point
  3. Often or most of the time 2 point
  4. All of the time 25 point

Question 3. Has your nausea been mostly:

  1. Varying ("comes and goes") 1point
  2. Constant 2 point

Question 4. What was the duration of your feeling of nausea (in hours)?

…, … (hours). If answer to Q1=c), score=50 Otherwise, select the highest score of Q1 or Q2, the multiply x Q3 x Q4

Postoperative nausea and vomiting intensity score:

Postoperative 24 hours
Postoperative nausea and vomits intensity scale (72. hours)
Time Frame: Postoperative 72 hours

Question 1. Have you vomited or had dry-retching?

  1. No 0 point
  2. Once or twice 2 point
  3. Three or more times 50 points

Question 2. Have you experienced a feeling of nausea? If yes, has your feeling interfered with being able to get out of bed, walking, eating or drinking?

  1. No 0 point
  2. Sometimes 1 point
  3. Often or most of the time 2 point
  4. All of the time 25 point

Question 3. Has your nausea been mostly:

  1. Varying ("comes and goes") 1point
  2. Constant 2 point

Question 4. What was the duration of your feeling of nausea (in hours)?

…, … (hours). If answer to Q1=c), score=50 Otherwise, select the highest score of Q1 or Q2, the multiply x Q3 x Q4 Postoperative nausea and vomiting intensity score:

Postoperative 72 hours
Quality of life (index)
Time Frame: Baseline (Index)

The EuroQol Group (EQ-5D-5L) questionnaire will be used to evaluate quality of life.

According to the survey, patients will be evaluated in five areas (mobility, self-care, usual activities, pain, and anxiety).

Baseline (Index)
Quality of life (24. hours)
Time Frame: Postoperative 24 hours

The EuroQol Group (EQ-5D-5L) questionnaire will be used to evaluate quality of life.

According to the survey, patients will be evaluated in five areas (mobility, self-care, usual activities, pain, and anxiety).

Postoperative 24 hours
Quality of life (72. hours)
Time Frame: Postoperative 72 hours

The EuroQol Group (EQ-5D-5L) questionnaire will be used to evaluate quality of life.

According to the survey, patients will be evaluated in five areas (mobility, self-care, usual activities, pain, and anxiety).

Postoperative 72 hours
Quality of life (1. month)
Time Frame: Postoperative 1 month

The EuroQol Group (EQ-5D-5L) questionnaire will be used to evaluate quality of life.

According to the survey, patients will be evaluated in five areas (mobility, self-care, usual activities, pain, and anxiety).

Postoperative 1 month
Postoperative nausea and vomiting intensity scale (1. month)
Time Frame: Postoperative 1 month

Question 1. Have you vomited or had dry-retching?

  1. No 0 point
  2. Once or twice 2 point
  3. Three or more times 50 points

Question 2. Have you experienced a feeling of nausea? If yes, has your feeling interfered with being able to get out of bed, walking, eating or drinking?

  1. No 0 point
  2. Sometimes 1 point
  3. Often or most of the time 2 point
  4. All of the time 25 point

Question 3. Has your nausea been mostly:

  1. Varying ("comes and goes") 1point
  2. Constant 2 point

Question 4. What was the duration of your feeling of nausea (in hours)?

…, … (hours). If answer to Q1=c), score=50 Otherwise, select the highest score of Q1 or Q2, the multiply x Q3 x Q4

Postoperative nausea and vomiting intensity score:

Postoperative 1 month

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Age
Time Frame: 1 day First application
Years
1 day First application
Body Mass Index (Index)
Time Frame: 1 day First application
kg/m2
1 day First application
Body mass Index
Time Frame: Postoperative 1 month
kg/m2
Postoperative 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2023

Primary Completion (Estimated)

June 30, 2024

Study Completion (Estimated)

July 30, 2024

Study Registration Dates

First Submitted

November 2, 2023

First Submitted That Met QC Criteria

November 29, 2023

First Posted (Actual)

November 30, 2023

Study Record Updates

Last Update Posted (Actual)

November 30, 2023

Last Update Submitted That Met QC Criteria

November 29, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • E-16214662-050.01.04-254590-62

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nausea, Postoperative

Clinical Trials on Postoperative Nausea and Vomiting scala

Subscribe